Gastric retained gabapentin dosage form
AssigneeDepomed, Inc.
InventorsBret Berner, Sui Yuen Eddie Hou, Gloria M. Gusler
Life of this patent
Estimating the term…
Abstract
A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.
Claims20
A dosage form, comprising between about 100 mg to about 4800 mg of gabapentin or pharmaceutically acceptable salt thereof, dispersed in a single polymer matrix comprising at least one swellable hydrophilic polymer that swells unrestrained dimensionally by imbibing water to increase its size to promote gastric retention of the dosage form in a stomach in a fed mode, wherein upon contact with water, gabapentin is released by diffusion from the dosage form over a period of at least five hours and at least 40 wt % of the gabapentin is retained in the dosage form 1 hour after administration.
Dependencies are inferred from the claim text.